Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 48-54

  Mavroudis, D ^a   Papakotoulas, P ^b   Ardavanis, A ^c   Syrigos, K ^d   Kakolyris, S ^e   Ziras, N ^f   Kouroussis, C ^b   Malamos, N ^g   Polyzos, A ^h   Christophyllakis, C ⁱ   Kentepozidis, N ^j   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c Agios Savvas Anticancer Hospital of Athens   (Greece)

^d KAT HOSPITAL   (Greece)

^e DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

^g Elena Iliadi Hospital   (Greece)

^h LAIKO GENERAL HOSPITAL   (Greece)

ⁱ 401 Military Hospital of Athens   (Greece)

^j IASO GENERAL HOSPITAL   (Greece)

more..

Author keywords

Capecitabine; Chemotherapy; Docetaxel; Epirubicin; Metastatic breast cancer

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77949326810     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp498     Document Type: Article

References (21)

1. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
2. Pacilio C, Morabito A, Nuzzo F et al. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 2006; 94: 1233-1336.
3. Kouroussis C, Xydakis E, Potamianou A et al. Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG). Ann Oncol 1999; 10: 547-552.
4. Mavroudis D, Alexopoulos A, Ziras N et al. Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol 2000; 11: 1249-1254.
5. Bonneterre J, Dieras V, Tubiana-Hulin M et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 91: 1466-1471.
6. Morales S, Lorenzo A, Ramos M et al. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study. Cancer Chemother Pharmacol 2004; 53: 75-78.
7. Hainsworth JD, Yardley DA, Spigel DR et al. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. Cancer Invest 2006; 24: 469-473.
8. Salminen E, Syvänen K, Korpela J et al. Docetaxel with epirubicin-investigations on cardiac safety. Anticancer Drugs 2003; 14: 73-77.
9. Malinovszky K, Johnston S, Barrett-Lee P et al. TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemother Pharmacol 2007; 59: 413-418.
10. Cardoso F, Castiglione M. Locally recurrent or metastatic breast cancer: eSMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl 4): iv15-iv18.
11. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
12. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
13. Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17: 1379-1385.
14. Verma S, Maraninchi D, O'Shaughnessy J et al. Capecitabine plus docetaxel combination therapy. Cancer 2005; 103: 2455-2465.
15. Altman GD. Practical Statistics for Medical Research. London: Chapman and Hall 1991; 23-57.
16. Collett D. Modeling Survival Data in Medical Research. London: Chapman and Hall 1994; 53-106.
17. Armitage P, Berry G. Statistical Methods in Medical Research. 3rd edition, Oxford: Blackwell Scientific 1994; 503-524.
18. Lück H-J, du Bois A, Schrader I et al. Final results of the AGO breast cancer study group MAMMA-3 trial: first-line capecitabine + paclitaxel vs epirubicin + paclitaxel for high-risk metastatic breast cancer. San Antonio Breast Cancer Symposium 2007; (Abstr 1076).
19. Chan S, Romieu G, Huober J et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009; 27: 1753-1760.
20. Silva O, Lopes G, Morgenzstern D et al. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Clin Breast Cancer 2008; 8: 162-167.
21. Puglisi F, Cardellino GG, Crivellari D et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxelmodulated capecitabine for metastatic breast cancer. Ann Oncol 2008; 19: 1541-1546.